Patents by Inventor Adrian D. Hobson

Adrian D. Hobson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTI-CD19 ANTIBODY DRUG CONJUGATES
    Publication number: 20240100181
    Abstract: The present disclosure provides anti-CD19 antibody drug conjugates (ADCs), including compositions and methods of using such ADCs.
    Type: Application
    Filed: June 15, 2023
    Publication date: March 28, 2024
    Inventors: Chewei A. Chang, Ethan D. Emberley, Adrian D. Hobson, Christopher C. Marvin, James W. Purcell
  • NUCLEAR RECEPTOR MODULATORS
    Publication number: 20230066771
    Abstract: The invention provides compounds of Formula (I) pharmaceutically acceptable salts, thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological conditions.
    Type: Application
    Filed: July 23, 2021
    Publication date: March 2, 2023
    Inventors: Maria A. Argiriadi, Eric C. Breinlinger, Kevin P. Cusack, Adrian D. Hobson, Dominique Potin, Martine Barth, Jerome Amaudrut, Olivia Poupardin, Laurent Mounier, Michael E. Kort
  • GLUCOCORTICOID RECEPTOR AGONIST AND IMMUNOCONJUGATES THEREOF
    Publication number: 20220354959
    Abstract: Provided herein are glucocorticoid receptor agonist immunoconjugates, glucocorticoid receptor agonists, and methods of using the same, e.g., to treat autoimmune or inflammatory diseases.
    Type: Application
    Filed: May 12, 2021
    Publication date: November 10, 2022
    Applicant: AbbVie Inc.
    Inventors: Michael J. McPherson, Adrian D. Hobson, Martin E. Hayes, Christopher C. Marvin, Diana Schmidt, Wendy Waegell, Christian Goess, Jason Z. Oh, Axel Hernandez, Jr., John T. Randolph
  • ANTI-CD40 ANTIBODY DRUG CONJUGATES
    Publication number: 20220265842
    Abstract: Provided herein are anti-CD40 antibody drug conjugates comprising a radical of Formula (I), wherein R1, R2, and R3 are as defined herein. Further provided are anti-CD40 antibody drug conjugates of Formula (II), wherein Z, R, AA1, AA2, AA3, m, p, q, n, w, R1, R2, and R3 are as defined herein. Further provided are pharmaceutical compositions and kits thereof, and methods of using same.
    Type: Application
    Filed: November 29, 2018
    Publication date: August 25, 2022
    Applicant: AbbVie Inc.
    Inventors: Adrian D. Hobson, Jason Z. Oh, Michael J. McPherson, Wendy Waegell, Shaughn H. Bryant, Axel Hernandez, Jr., Claire L. Ihle, Christopher C. Marvin, Olivia A. Perng, Ling C. Santora, Lu Wang, Lu Wang
  • NUCLEAR RECEPTOR MODULATORS
    Publication number: 20210130293
    Abstract: The invention provides compounds of Formula (I) pharmaceutically acceptable salts, thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological conditions.
    Type: Application
    Filed: October 16, 2019
    Publication date: May 6, 2021
    Inventors: Maria A. Argiriadi, Eric C. Breinlinger, Kevin P. Cusack, Adrian D. Hobson, Dominique Potin, Martine Barth, Jerome Amaudrut, Olivia Poupardin, Laurent Mounier, Michael E. Kort
  • GLUCOCORTICOID RECEPTOR AGONIST AND IMMUNOCONJUGATES THEREOF
    Publication number: 20210015938
    Abstract: Provided herein are glucocorticoid receptor agonist immunoconjugates, glucocorticoid receptor agonists, and methods of using the same.
    Type: Application
    Filed: July 31, 2020
    Publication date: January 21, 2021
    Applicant: AbbVie Inc.
    Inventors: Adrian D. Hobson, Michael J. McPherson, Wendy Waegell, Christian Goess, Axel Hernandez, Jr., Lu Wang, Lu Wang, Christopher C. Marvin, Ling C. Santora
  • GLUCOCORTICOID RECEPTOR AGONIST AND IMMUNOCONJUGATES THEREOF
    Publication number: 20200338208
    Abstract: Provided herein are glucocorticoid receptor agonist immunoconjugates, glucocorticoid receptor agonists, and methods of using the same, e.g., to treat autoimmune or inflammatory diseases.
    Type: Application
    Filed: April 16, 2020
    Publication date: October 29, 2020
    Applicant: AbbVie Inc.
    Inventors: Michael J. McPherson, Adrian D. Hobson, Martin E. Hayes, Christopher C. Marvin, Diana Schmidt, Wendy Waegell, Christian Goess, Jason Z. Oh, Axel Hernandez, JR., John T. Randolph
  • Glucocorticoid receptor agonist and immunoconjugates thereof
    Patent number: 10668167
    Abstract: Provided herein are glucocorticoid receptor agonist immunoconjugates, glucocorticoid receptor agonists, and methods of using the same, e.g., to treat autoimmune or inflammatory diseases.
    Type: Grant
    Filed: May 10, 2019
    Date of Patent: June 2, 2020
    Assignee: AbbVie Inc.
    Inventors: Michael J. McPherson, Adrian D. Hobson, Martin E. Hayes, Christopher C. Marvin, Diana Schmidt, Wendy Waegell, Christian Goess, Jason Z. Oh, Axel Hernandez, Jr., John T. Randolph
  • GLUCOCORTICOID RECEPTOR AGONIST AND IMMUNOCONJUGATES THEREOF
    Publication number: 20190262465
    Abstract: Provided herein are glucocorticoid receptor agonist immunoconjugates, glucocorticoid receptor agonists, and methods of using the same, e.g., to treat autoimmune or inflammatory diseases.
    Type: Application
    Filed: May 10, 2019
    Publication date: August 29, 2019
    Applicant: AbbVie Inc.
    Inventors: Michael J. MCPHERSON, Adrian D. HOBSON, Martin E. HAYES, Christopher C. MARVIN, Diana SCHMIDT, Wendy WAEGELL, Christian GOESS, Jason Z. OH, Axel HERNANDEZ, Jr., John T. RANDOLPH
  • NUCLEAR RECEPTOR MODULATORS
    Publication number: 20190055196
    Abstract: The invention provides compounds of Formula (I) pharmaceutically acceptable salts, thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological conditions.
    Type: Application
    Filed: August 22, 2018
    Publication date: February 21, 2019
    Inventors: Maria A. Argiriadi, Eric C. Breinlinger, Kevin P. Cusack, Adrian D. Hobson, Dominique Potin, Martine Barth, Jerome Amaudrut, Olivia Poupardin, Laurent Mounier, Michael E. Kort
  • Nuclear receptor modulators
    Patent number: 10106501
    Abstract: The invention provides compounds of Formula (I) pharmaceutically acceptable salts, thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological conditions.
    Type: Grant
    Filed: June 8, 2016
    Date of Patent: October 23, 2018
    Assignee: AbbVie Inc.
    Inventors: Maria A. Argiriadi, Eric C. Breinlinger, Kevin P. Cusack, Adrian D. Hobson, Dominique Potin, Martine Barth, Jerome Amaudrut, Olivia Poupardin, Laurent Mounier, Michael E. Kort
  • GLUCOCORTICOID RECEPTOR AGONIST AND IMMUNOCONJUGATES THEREOF
    Publication number: 20180126000
    Abstract: Provided herein are glucocorticoid receptor agonist immunoconjugates, glucocorticoid receptor agonists, and methods of using the same, e.g., to treat autoimmune or inflammatory diseases.
    Type: Application
    Filed: June 1, 2017
    Publication date: May 10, 2018
    Applicant: AbbVie Inc.
    Inventors: Michael J. MCPHERSON, Adrian D. HOBSON, Martin E. HAYES, Christopher C. MARVIN, Diana SCHMIDT, Wendy WAEGELL, Christian GOESS, Jason Z. OH, Axel HERNANDEZ, JR., John T. RANDOLPH
  • NUCLEAR RECEPTOR MODULATORS
    Publication number: 20160362370
    Abstract: The invention provides compounds of Formula (I) pharmaceutically acceptable salts, thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological conditions.
    Type: Application
    Filed: June 8, 2016
    Publication date: December 15, 2016
    Applicant: AbbVie Inc.
    Inventors: Maria A. Argiriadi, Eric C. Breinlinger, Kevin P. Cusack, Adrian D. Hobson, Dominique Potin, Martine Barth, Jerome Amaudrut, Olivia Poupardin, Laurent Mounier, Michael E. Kort
  • 5-substituted indazoles as kinase inhibitors
    Patent number: 9163007
    Abstract: The present invention relates to compounds of formula (I) or pharmaceutical acceptable salts, wherein A, R1, R2, R3 and m, are defined in the description. The present invention relates also to methods of making said compounds, and compositions containing said compounds which are useful for inhibiting kinases such as Glycogen Synthase kinase 3 (GSK-3), Rho kinase (ROCK), Janus Kinases (JAK), Cdc7, AKT, PAK4, PLK, CK2, KDR, MK2, JNK1, aurora, pim 1 and nek 2.
    Type: Grant
    Filed: December 20, 2013
    Date of Patent: October 20, 2015
    Assignee: AbbVie Inc.
    Inventors: Irini Akritopoulou-Zanze, Brian D. Wakefield, Helmut Mack, Sean C. Turner, Alan F. Gasiecki, Vijaya J. Gracias, Kathy A. Sarris, Douglas M. Kalvin, Melissa J. Michmerhuizen, Qi Shuai, Jyoti R. Patel, Margaretha H. M. Bakker, Nicole Teusch, Eric F. Johnson, Peter J. Kovar, Stevan W. Djuric, Andrew J. Long, Anil Vasudevan, Dawn M. George, Lu Wang, Biqin Li, Nigel S. Moore, Adrian D. Hobson, Keith W. Woods, Julie M. Miyashiro, Steven L. Swann, Jr., Thomas D. Penning
  • Substituted 2,10-dihydro-9-oxa-1,2,4A-triazaphenanthren-3-ones and uses thereof
    Patent number: 9115151
    Abstract: The invention provides a compound of Formula (I) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological and oncological conditions.
    Type: Grant
    Filed: March 19, 2014
    Date of Patent: August 25, 2015
    Assignee: AbbVie Inc.
    Inventors: Dawn M. George, Maria A. Argiriadi, Martine Barth, Dominique Bonafoux, Eric C. Breinlinger, Linlin Dai, Jeremy Edmunds, Michael M. Friedman, Fabrice Guillier, Adrian D. Hobson, Dominique Potin, Didier Thomas, Jianfei Wang, Wentao Wu, Yang Zhang
  • 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS
    Publication number: 20140343066
    Abstract: The present invention relates to compounds of formula (I) or pharmaceutical acceptable salts, wherein A, R1, R2, R3 and m, are defined in the description. The present invention relates also to methods of making said compounds, and compositions containing said compounds which are useful for inhibiting kinases such as Glycogen Synthase kinase 3 (GSK-3), Rho kinase (ROCK), Janus Kinases (JAK), Cdc7, AKT, PAK4, PLK, CK2, KDR, MK2, JNK1, aurora, pim 1 and nek 2.
    Type: Application
    Filed: December 20, 2013
    Publication date: November 20, 2014
    Inventors: Irini Akritopoulou-Zanze, Brian D. Wakefield, Helmut Mack, Sean C. Turner, Alan F. Gasiecki, Vijaya J. Gracias, Kathy A. Sarris, Douglas M. Kalvin, Melissa J. Michmerhuizen, Qi Shuai, Jyoti R. Patel, Margaretha H.M. Bakker, Nicole Teusch, Eric F. Johnson, Peter J. Kovar, Stevan W. Djuric, Andrew J. Long, Anil Vasudevan, Dawn M. George, Lu Wang, Biqin Li, Nigel S. Moore, Adrian D. Hobson, Keith W. Woods, Julie M. Miyashiro, Steven L. Swann, Jr., Thomas D. Penning
  • TRIAZINONE COMPOUNDS
    Publication number: 20140206663
    Abstract: The invention provides a compound of Formula (I) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological and oncological conditions.
    Type: Application
    Filed: March 19, 2014
    Publication date: July 24, 2014
    Inventors: Jianfei Wang, Eric C. Breinlinger, Martine Barth, Michael M. Friedman, Fabrice Guillier, Maria A. Argiriadi, Jeremy Edmunds, Dominique Potin, Adrian D. Hobson, Wentao Wu, Dominique Bonafoux, Didier Thomas, Dawn M. George, Linlin Dai, Yang Zhang
  • Aminopyrrolidines as chemokine receptor antagonists
    Patent number: 8754107
    Abstract: The present invention is directed to novel aminopyrrolidines of formula I pharmaceutically acceptable salts thereof, metabolites thereof, isomers thereof, stereoisomers thereof or pro-drugs thereof, wherein the variables are as defined herein. The compounds of formula (I) are useful as chemokine receptor antagonists and as such would be useful in treating certain conditions and diseases, especially inflammatory conditions and diseases and proliferative disorders and conditions, for example, cancers.
    Type: Grant
    Filed: November 16, 2007
    Date of Patent: June 17, 2014
    Assignee: AbbVie Inc.
    Inventors: Dawn M. George, Richard W. Dixon, Michael Friedman, Adrian D. Hobson, Biqin Li, Lu Wang, Xiaoyun Wu, Neil Wishart
  • 5-substituted indazoles as kinase inhibitors
    Patent number: 8648069
    Abstract: The present invention relates to compounds of formula (I) or pharmaceutical acceptable salts, wherein A, R1, R2, R3 and m, are defined in the description. The present invention relates also to methods of making said compounds, and compositions containing said compounds which are useful for inhibiting kinases such as Glycogen Synthase kinase 3 (GSK-3), Rho kinase (ROCK), Janus Kinases (JAK), Cdc7, AKT, PAK4, PLK, CK2, KDR, MK2, JNK1, aurora, pim 1 and nek 2.
    Type: Grant
    Filed: December 4, 2008
    Date of Patent: February 11, 2014
    Assignee: AbbVie Inc.
    Inventors: Irini Akritopoulou-Zanze, Brian D. Wakefield, Helmut Mack, Sean C. Turner, Alan F. Gasiecki, Vijaya J. Gracias, Kathy A. Sarris, Douglas M. Kalvin, Melissa J. Michmerhuizen, Qi Shuai, Jyoti R. Patel, Margaretha Bakker, Nicole Teusch, Eric F. Johnson, Peter J. Kovar, Stevan W. Djuric, Andrew J. Long, Anil Vasudevan, Dawn George, Lu Wang, Biqin Li, N. St. John Moore, Adrian D. Hobson, Keith W. Woods, Julie M. Miyashiro, Steven L. Swann, Jr., Thomas D. Penning
  • NOVEL TRICYCLIC COMPOUNDS
    Publication number: 20130072470
    Abstract: The invention provides compounds of Formula (I) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological and oncological conditions.
    Type: Application
    Filed: September 20, 2012
    Publication date: March 21, 2013
    Applicant: ABBVIE INC.
    Inventors: Neil Wishart, Dominique F. Bonafoux, Kristine E. Frank, Adrian D. Hobson, Donald B. Konopacki, Gloria Y. Martinez, Lu Wang